1
|
Rossini B, Cecchi N, Clemente F, De Paolis MR, Hohaus S, Innao V, Lucignano M, Massaiu R, Palumbo G, Rigolin GM, Rossi FG, Verga L, Guarini A. Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences. Drugs Context 2024; 13:2023-9-4. [PMID: 38510313 PMCID: PMC10954290 DOI: 10.7573/dic.2023-9-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 01/24/2024] [Indexed: 03/22/2024] Open
Abstract
Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant. This collection of clinical experiences focuses on patients treated with siltuximab therapy, particularly regarding the idiopathic multicentric CD diagnostic work-up, and on treatment administration in patients with complex disease entering differential diagnosis with CD or concomitant diseases. Thus, these data help further characterize and improve the use of siltuximab in real practice in terms of effectiveness and safety of long-term administration as well as consequences of treatment interruption.
Collapse
Affiliation(s)
- Bernardo Rossini
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, Italy
| | - Nicola Cecchi
- Dipartimento di Oncologia ed Emato-Oncologia, Università degli studi di Milano, Milan, Italy
- Haematology Department, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Felice Clemente
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, Italy
| | - Maria Rosaria De Paolis
- Hematology and Stem Cell Transplant Unit, ‘Vito Fazzi’ Hospital, Piazza Filippo Muratore, Lecce, Italy
| | - Stefan Hohaus
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - Vanessa Innao
- U.O.C. Ematologia – A.R.N.A.S. Garibaldi, Catania, Italy
| | - Mariano Lucignano
- Hematology and Autotransplant Unit “A. Tortora” Hospital, Pagani, Salerno, Italy
| | - Roberto Massaiu
- SC di Ematologia e Trapianti di Midollo Osseo, Azienda Ospedaliero-Universitaria, Sassari, Italy
| | - Giovanna Palumbo
- A.O.U Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | | | - Francesca Gaia Rossi
- Haematology Department, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Luisa Verga
- Hematology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - Attilio Guarini
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, Italy
| |
Collapse
|
2
|
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. Haematologica 2024; 109:245-255. [PMID: 37439329 PMCID: PMC10772491 DOI: 10.3324/haematol.2023.283251] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Accepted: 07/06/2023] [Indexed: 07/14/2023] Open
Abstract
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved to have a superior clinical benefit over pomalidomide and dexamethasone with a manageable toxicity profile, leading to its approval for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. We report here a real-world experience of 200 cases of RRMM treated with EloPd in 35 Italian centers outside of clinical trials. In our dataset, the median number of prior lines of therapy was two, with 51% of cases undergoing autologous stem cell transplant and 73% having been exposed to daratumumab. After a median follow-up of 9 months, 126 patients had stopped EloPd, most of them (88.9%) because of disease progression. The overall response rate was 55.4%, a finding in line with the pivotal trial results. Regarding adverse events, the toxicity profile in our cohort was similar to that in the ELOQUENT-3 trial, with no significant differences between younger (<70 years) and older patients. The median progression-free survival was 7 months, which was shorter than that observed in ELOQUENT-3, probably because of the different clinical characteristics of the two cohorts. Interestingly, International Staging System stage III disease was associated with worse progression-free survival (hazard ratio=2.55). Finally, the median overall survival of our series was shorter than that observed in the ELOQUENT-3 trial (17.5 vs. 29.8 months). In conclusion, our real-world study confirms that EloPd is a safe and possible therapeutic choice for patients with RRMM who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Collapse
Affiliation(s)
- Massimo Gentile
- Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende.
| | - Ernesto Vigna
- Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza
| | | | - Monica Galli
- Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo
| | | | - Roberto Mina
- Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino
| | - Roberta Della Pepa
- Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples
| | - Renato Zambello
- University of Padova, Department of Medicine, Hematology Unit, Italy; Veneto Institute of Molecular Medicine, Padova
| | | | - Antonella Bruzzese
- Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza
| | - Silvia Mangiacavalli
- Hematology Division, Department of Hematology-Oncology, IRCCS Fondazione Policlinico San Matteo, Pavia
| | - Elena Zamagni
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna
| | | | - Maurizio Musso
- Onco-Hematology Unit and TMO U.O.C., Departiment of Oncology, Palermo
| | - Concetta Conticello
- Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania
| | - Claudio Cerchione
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
| | - Giuseppe Mele
- Department of Hematology, Hospital Perrino, Brindisi
| | | | | | | | - Gloria Margiotta Casaluci
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara
| | - Angela Rago
- Haematology Unit, ASL ROMA 1 Santo Spirito Hospital of Rome Rome Italy
| | - Roberto Ria
- Department of Biomedical Science, Internal Medicine "G. Baccelli", Policlinico, University of Bari "Aldo Moro" Medical School, Bari
| | | | - Gregorio Barilà
- University of Padova, Department of Medicine, Hematology Unit, Italy; Veneto Institute of Molecular Medicine, Padova
| | - Gaetano Palumbo
- Department of Hematology, Hospital University Riuniti, Foggia
| | - Alessandra Pompa
- Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano
| | - Donatella Vincelli
- Department of Hemato-Oncology and Radiotherapy, Hematology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria
| | - Marino Brunori
- Internal Medicine, Ospedale S. Croce, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano
| | - Fabrizio Accardi
- Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia- Cervello, Palermo
| | | | - Angela Amendola
- Hematology Unit, Azienda Ospedaliera Regionale "San Carlo", Potenza
| | - Raffaele Fontana
- Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno
| | - Velia Bongarzoni
- Department of Hematology San Giovanni-Addolorata Hospital Rome Italy
| | | | - Emilia Cotzia
- Section of Hematology- Ospedale E. Muscatello-Augusta, Siracusa
| | - Alessandro Gozzetti
- Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena
| | - Rita Rizzi
- Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari
| | - Nicola Sgherza
- Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari
| | - Eleonora Ferretti
- Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia
| | - Giuseppe Bertuglia
- Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino
| | - Davide Nappi
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
| | - Maria Teresa Petrucci
- Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Rome
| | - Francesco Di Raimondo
- Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania
| | - Antonino Neri
- Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia.
| | | | - Pellegrino Musto
- Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari
| |
Collapse
|
3
|
Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, Pastore D. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese". Leuk Lymphoma 2023; 64:1715-1718. [PMID: 37417467 DOI: 10.1080/10428194.2023.2232487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 06/24/2023] [Indexed: 07/08/2023]
Affiliation(s)
| | | | - Nicola Cascavilla
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy
| | - Angelo Michele Carella
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy
| | | | | | | | - Vincenzo Pavone
- Haematology, Ospedale Cardinale Panico, Tricase (Lecce), Italy
| | | | - Paola Curci
- Policlinico, University of Bari Medical School, Bari, Italy
| | | | - Candida Germano
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta (Bari), Italy
| | - Anna Mele
- Haematology, Ospedale Cardinale Panico, Tricase (Lecce), Italy
| | | | | | | | | | - Giovanni Reddiconto
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy
| | | | | | - Nicola Sgherza
- Policlinico, University of Bari Medical School, Bari, Italy
| | | | | | | |
Collapse
|
4
|
Mele A, Prete E, Citiso S, Mele G, Pastore D, Sgherza N, Curci P, Musto P, Falcone AP, Cascavilla N, Germano C, Giuseppe T, Reddiconto G, Di Renzo N, Palazzo G, Mazza P, Rossini B, Guarini A, Palumbo G, Melillo LMA, Pavone V. PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP). Hemasphere 2022. [PMCID: PMC9431550 DOI: 10.1097/01.hs9.0000850896.11254.d1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'. Ann Hematol 2022; 101:1727-1739. [PMID: 35587825 DOI: 10.1007/s00277-022-04857-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 04/24/2022] [Indexed: 12/01/2022]
Abstract
We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalidomide as salvage therapy at 9 haematological centres in Puglia. Choice of both regimens was based on previous treatment and/or physicians' preference. Considering the under-representation of older patients (very old patient ≥ 80 years) in clinical trials and the prognostic and predictive importance and value of frailty status, here, we further characterised the patient cohort by age. The overall response rate (ORR) was generally lower than what was previously reported in the CASTOR (ORR 72.6% vs 85%) and POLLUX (ORR 86.5% vs 93%) trials. The lower ORR in our analysis compared to the CASTOR and POLLUX trials could be related to a less selected population. Similarly, amongst very old patients, the ORR was encouraging: ORR to treatment with DVd (daratumumab + bortezomib + dexamethasone) was 66.7%, and ORR to treatment with DRd (daratumumab + lenalidomide + dexamethasone) was 92.3%. Median TTP (time to progression) was 10.8 months (1-year TTP: 44.7%; 2-year TTP: 25.3%) in the DVd group; median TTP was not reached in the DRd group (1-year TTP: 82.7%; 2-year TTP: 71.4%). Median OS (overall survival) was not reached either in the DRd group (1-year OS: 85.9%; 2-year OS: 73.7%) or the DVd group (1-year OS: 70.2%; 2-year OS: 58.9%).
Collapse
Affiliation(s)
- G Mele
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy.
| | - N Cascavilla
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - N Di Renzo
- Haematology, Ospedale V. Fazzi, Lecce, Italy
| | - A Guarini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - P Mazza
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - L Melillo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | - V Pavone
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Tarantini
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - P Curci
- University of Bari Medical School, Policlinico, Bari, Italy
| | - A P Falcone
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - C Germano
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - A Mele
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Palazzo
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - G Palumbo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | | | - B Rossini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - G Specchia
- University of Bari Medical School, Policlinico, Bari, Italy
| | - P Musto
- University of Bari Medical School, Policlinico, Bari, Italy
| | - D Pastore
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy
| |
Collapse
|
6
|
Zaccaria GM, Colella V, Colucci S, Clemente F, Pavone F, Vegliante MC, Esposito F, Opinto G, Scattone A, Loseto G, Minoia C, Rossini B, Quinto AM, Angiulli V, Grieco LA, Fama A, Ferrero S, Moia R, Di Rocco A, Quaglia FM, Tabanelli V, Guarini A, Ciavarella S. Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology. Sci Rep 2021; 11:23823. [PMID: 34893665 PMCID: PMC8664934 DOI: 10.1038/s41598-021-03204-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 11/23/2021] [Indexed: 12/04/2022] Open
Abstract
The unstructured nature of Real-World (RW) data from onco-hematological patients and the scarce accessibility to integrated systems restrain the use of RW information for research purposes. Natural Language Processing (NLP) might help in transposing unstructured reports into standardized electronic health records. We exploited NLP to develop an automated tool, named ARGO (Automatic Record Generator for Onco-hematology) to recognize information from pathology reports and populate electronic case report forms (eCRFs) pre-implemented by REDCap. ARGO was applied to hemo-lymphopathology reports of diffuse large B-cell, follicular, and mantle cell lymphomas, and assessed for accuracy (A), precision (P), recall (R) and F1-score (F) on internal (n = 239) and external (n = 93) report series. 326 (98.2%) reports were converted into corresponding eCRFs. Overall, ARGO showed high performance in capturing (1) identification report number (all metrics > 90%), (2) biopsy date (all metrics > 90% in both series), (3) specimen type (86.6% and 91.4% of A, 98.5% and 100.0% of P, 92.5% and 95.5% of F, and 87.2% and 91.4% of R for internal and external series, respectively), (4) diagnosis (100% of P with A, R and F of 90% in both series). We developed and validated a generalizable tool that generates structured eCRFs from real-life pathology reports.
Collapse
Affiliation(s)
- Gian Maria Zaccaria
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy.
| | - Vito Colella
- Department of Electrical and Information Engineering, Politecnico of Bari, Bari, Italy
| | - Simona Colucci
- Department of Electrical and Information Engineering, Politecnico of Bari, Bari, Italy
| | - Felice Clemente
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Fabio Pavone
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Maria Carmela Vegliante
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Flavia Esposito
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy.,Department of Mathematics, University of Bari Aldo Moro, Bari, Italy
| | - Giuseppina Opinto
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Anna Scattone
- Pathology Department, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - Giacomo Loseto
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Carla Minoia
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Bernardo Rossini
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Angela Maria Quinto
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Vito Angiulli
- Clinical Engineering Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - Luigi Alfredo Grieco
- Department of Electrical and Information Engineering, Politecnico of Bari, Bari, Italy
| | - Angelo Fama
- Hematology, Azienda USL - IRCCS Di Reggio Emilia, Reggio Emilia, Italy
| | - Simone Ferrero
- Division of Hematology 1, AOU "Città Della Salute e Della Scienza di Torino", Torino, Italy.,Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy
| | - Riccardo Moia
- Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore Della Carità Di Novara, Novara, Italy
| | - Alice Di Rocco
- Unit of Hematology, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy
| | | | - Valentina Tabanelli
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milano, Italy
| | - Attilio Guarini
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| | - Sabino Ciavarella
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco, 65, Bari, Italy
| |
Collapse
|
7
|
Maggialetti N, Ferrari C, Nappi AG, Quinto A, Rossini B, Zappia M, Minoia C, Guarini A, Brunese L, Rubini G. Is whole body low dose CT still necessary in the era of 18F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients? Hell J Nucl Med 2020; 23:264-271. [PMID: 33306757 DOI: 10.1967/s002449912206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 11/17/2019] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Whole body low dose computed tomography (WBLDCT) is the first-choice imaging modality to identify bone involvement in multiple myeloma (MM). Because the unenhanced LDCT co-registered to positron emission tomography (PET) (LDCT/PET) has similar technical characteristics to WBLDCT, we aimed to assess its reliability in the detection of bone disease, for employing fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT as unique multimodality imaging method in MM patients. SUBJECTS AND METHODS Thirty three consecutive MM patients were prospectively enrolled and evaluated with WBLDCT to assess bone involvement. In addition, patients underwent 18F-FDG PET/CT using a disease-tailored optimized LDCT protocol. To compare both methods, skeletal anatomical regions were identified and a per-region and per-patient analysis were performed using Cohen's k test. Low dose computed tomography/PET sensitivity, specificity and accuracy were also calculated. RESULTS The two imaging modalities resulted highly concordant considering both patient-based (k=0.841) and region-based analysis; some discrepancies were observed in dorsal spine (k=0.809) and thorax (k=0.756). Low dose computed tomography/PET sensitivity, specificity and accuracy were 89.4%, 98.3% and 93.5%, respectively. CONCLUSION Low dose computed tomography co-registered PET has comparable performance to WBLDCT. If confirmed on a lager sample, these encouraging results suggest the possibility to use this multimodal hybrid imaging as the only method for MM evaluation, rather than both exams, providing both morphologic and metabolic information in one session with impact on patient compliance, health care spending and especially radiation exposure.
Collapse
Affiliation(s)
- Nicola Maggialetti
- Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N. “Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”. Leuk Res 2015; 39:279-83. [DOI: 10.1016/j.leukres.2014.12.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 12/01/2014] [Accepted: 12/14/2014] [Indexed: 11/29/2022]
|
9
|
Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013; 98:1732-8. [PMID: 23812930 DOI: 10.3324/haematol.2013.085134] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse. Lenalidomide alone or in combination with rituximab has been shown to be active in relapsed/refractory aggressive lymphomas. In this phase I study we determined the maximum tolerated dose of lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in untreated, elderly (median age 68 years) patients with diffuse large B-cell lymphoma. Four lenalidomide doses (5, 10, 15, and 20 mg/day on days 1-14) allocated using the continual reassessment method were planned to be administered for 14 days in combination with each course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for a total of six courses. Seven cohorts of patients (n=3 in each cohort) were treated (total n=21) at 10, 20, 15, 15, 15, 10, and 10 mg of lenalidomide. Dose-limiting toxicities occurred in seven patients during the first three courses of treatment. The third dose-level of lenalidomide (15 mg/day) was selected as the maximum tolerated dose, with an estimated probability of dose-limiting toxicities of 0.345 (95% credibility interval 0.164-0.553). Grade 3-4 hematologic adverse events were: neutropenia in 28% of the courses, thrombocytopenia in 9%, and anemia in 3%. Non-hematologic toxicities were moderate: grade 4 increase of creatinine phosphokinase (n=1), grade 3 cardiac (n=2), grade 3 neurological (n=3), and grade 3 gastrointestinal (n=1). In this phase I study, the overall response rate was 90%, with 81% achieving complete remission. This combination regimen appears safe in elderly patients with diffuse large B-cell lymphoma and its efficacy will be assessed in the ongoing phase II trial. This trial was registered at www.clinicaltrials.gov as NCT00907348.
Collapse
|
10
|
Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol 2012; 229:87-98. [PMID: 22847671 DOI: 10.1002/path.4081] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Revised: 06/27/2012] [Accepted: 07/22/2012] [Indexed: 01/01/2023]
Abstract
Pentraxin 3 (PTX3) is a soluble pattern recognition receptor that binds with high affinity and selectivity to fibroblast growth factor-2 (FGF2), thus inhibiting its pro-angiogenic activity. Here we investigated the effects of PTX3 on monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patient-derived bone marrow (BM) plasma cells (PCs), endothelial cells (ECs), and fibroblasts (FBs), and assessed whether PTX3 can modulate the cross-talk between PCs and those microenvironment cells. PTX3 and FGF2 expression was evaluated by ELISA. Functional studies, including cell viability, wound healing, chemotaxis, and Matrigel(®) assays, were performed on MGUS and MM ECs and FBs upon the PTX3 treatment. Through western blot PTX3-induced modulation in FGF2/FGF receptor signalling pathways was evaluated in MGUS and MM ECs and FBs through western blot. Co-cultures between MM ECs/FBs and human PC lines were used to evaluate possible PTX3 indirect effects on MM PCs. Adhesion molecules were studied by flow cytometry. PTX3 provides a direct time- and dose-dependent apoptotic effect on MM ECs and FBs, but not on either MM primary PCs or human PC lines. PTX3 inhibits migration of MM ECs and FBs in a dose-dependent manner, and impacts in vitro and in vivo FGF2-mediated MM angiogenesis. Co-cultures of PCs and ECs/FBs show that PTX3 treatment indirectly impairs PC viability and adhesion. We conclude that PTX3 is an anti-angiogenic factor in MM and behaves as a cytotoxic molecule on MM cells by inhibiting the cross-talk between PCs and ECs/FBs.
Collapse
Affiliation(s)
- Antonio Basile
- Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A. Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma. Biol Blood Marrow Transplant 2012; 18:241-9. [DOI: 10.1016/j.bbmt.2011.07.014] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Accepted: 07/20/2011] [Indexed: 01/09/2023]
|
12
|
De Amici M, Villani M, Milanesi E, Rossini B, Barco S, Gerletti M, Ciprandi G. Adverse Reactions to Anaesthetics Prevented by the Use of Specific Laboratory Tests. EUR J INFLAMM 2011; 9:79-81. [DOI: 10.1177/1721727x1100900112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2023] Open
Abstract
Adverse reactions to general anaesthetics are quite rare, but may be very severe and even lethal. Unfortunately, the diagnosis is frequently based on medical history and few laboratory tests are reliable. A clinical case is presented: a patient, 75 years of age, was a candidate for urgent coronary artery bypass graft surgery due to the results of the coronary angiogram (severe stenosis of the main stem). The patient reported cardiac arrest in both operations with general anaesthesia, but there was a lack of clinical documentation. Thus, sulfidoleukotriene assay (CAST-ELISA, Bühlmann Laboratories) was used to determine the tolerability of general anesthetics in a single patient. The results of this in vitro test was useful in discriminating and excluding the administration of some widely-used standard anaesthetic agents.
Collapse
Affiliation(s)
- M. De Amici
- Fondazione IRCCS Policlinico San Matteo, S.C. di Pediatria, Pavia
| | - M.A. Villani
- Fondazione IRCCS Policlinico San Matteo, Rianimazione III, Pavia
| | - E. Milanesi
- Fondazione IRCCS Policlinico San Matteo, Rianimazione III, Pavia
| | - B. Rossini
- Fondazione IRCCS Policlinico San Matteo, Rianimazione III, Pavia
| | - S. Barco
- Fondazione IRCCS Policlinico San Matteo, S. C. Angiologia, Malattie Tromboemboliche, Pavia
| | - M. Gerletti
- Fondazione IRCCS Policlinico San Matteo, Rianimazione III, Pavia
| | - G. Ciprandi
- Department of Internal Medicine, Azienda Ospedaliera Universitaria San Martino, University of Genoa, Genoa
| |
Collapse
|
13
|
Meloni C, Ghezzi PM, Cipriani S, Petroni S, Tozzo C, Tatangelo P, Rossini B, Rossi V, Cecilia A, Casciani CU. Hemodiafiltration with post-dilution reinfusion of the regenerated ultrafiltrate: a new on-line technique. Clin Nephrol 2005; 63:106-12. [PMID: 15730052 DOI: 10.5414/cnp63106] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
AIMS All convective hemodiafiltration techniques require a replacement fluid, which must have an adequate electrolytic composition and must be sterile and pyrogen-free. Using an integrated adsorption cartridge, the ultrafiltrate can be "regenerated" and used as a replacement fluid (hemo-filtrate reinfusion; HFR). The aim of this study was to evaluate whether the HFR technique as suggested in its original configuration could be improved by inverting the purification sequence (post-dilution HFR; PDHFR) in order to increase the purification efficiency of the whole system. METHODS We performed standard HFR in 6 uremic patients during 6 months and, subsequently, during further 6 months, PDHFR. The dialytic efficacy of the two techniques and the filter blood loss were evaluated. Moreover, we studied how both techniques affected cytokine levels. RESULTS We observed a significant increase of urea extraction and of Kt/V values in PDHFR. An equally significant improvement was observed in regard to the extraction of beta2-m and the blood loss. Furthermore, IL6 and TNFalpha decreased significantly after PDHFR treatment. CONCLUSIONS HFR has proven to be an easy-to-perform hemodiafiltration technique, capable of resolving the typical problem of the other hemodiafiltration technique, the availability and production of a sterile and ultrapure reinfusion solution. The inversion of its configuration has allowed us to improve three aspects that have characterized, in our experience, the treatments performed in the original geometry: the removal of both urea and beta2-m, and the filter. Finally, it's notable that the decrease in cytokines levels achieved with PDHFR might attenuate the uremic micro-inflammatory state.
Collapse
Affiliation(s)
- C Meloni
- Nephrology and Dialysis Unit, St. Eugenio Hospital, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Meloni C, Ghezzi PM, Cipriani S, Rossi V, Tozzo C, Rossini B, Dominijanni S, Di Franco D, Cecilia A, Straccialano E, Casciani CU. [Long-term clinical experience in post-dilution HFR]. G Ital Nefrol 2004; 21 Suppl 30:S143-7. [PMID: 15750973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
PURPOSE Hemodiafiltration reinfusion (HFR) is characterized by the use of regenerated ultrafiltrate as replacement fluid. We devised a new technique, post-dilution HFR, aimed at increasing the purification efficiency, treatment tolerability and at reducing inflammatory state. METHODS We performed post-dilution HFR in six uremic patients during 18 months. Dialytic efficacy, filter blood rest and cytokine behavior were evaluated. RESULTS Neither pyrogenic reactions nor other adverse phenomena were recorded. The tolerance to the treatment was excellent. We observed a high rate of urea extraction and optimal Kt/V values, a high extraction of beta2 microglobulin (beta2-m) and a reduction in blood rest; in addition, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) significantly decreased. CONCLUSIONS. The inversion of the standard HFR configuration allowed us to improve the removal of both urea and beta2-m, and the blood rest, with an optimal tolerability. Moreover, the reduction in cytokine levels could attenuate the uremic microinflammatory state.
Collapse
Affiliation(s)
- C Meloni
- U.O.C. di Nefrologia e Dialisi, Ospedale S. Eugenio, Rome.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossini B, Cecilia A, Di Franco D, Straccialano E, Casciani CU. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14:208-13. [PMID: 15483780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023] Open
Abstract
OBJECTIVE To evaluate whether a dietary protein restriction is useful for slowing the progression of chronic renal failure (CRF) in diabetic and nondiabetic patients and to analyze the possible risk of malnutrition after such a dietary regimen. DESIGN Prospective, randomized case-control clinical trial. SETTING Nephrology outpatients. PATIENTS AND OTHER PARTICIPANTS A total of 169 patients, 89 affected with CRF and chronic hypertension and 80 affected with overt diabetic nephropathy (24 suffering from type 1 and 56 from type 2 diabetes) and chronic hypertension. INTERVENTION Diabetic patients and nondiabetic patients were randomly divided into 2 groups: 40 diabetic patients received a low-protein diet (0.8 g/kg/day) and 40 were maintained on a free protein diet; similarly, 44 nondiabetic patients received a low-protein diet (0.6 g/kg/day) and 45 were maintained on a free protein diet. The investigation lasted 1 year. MAIN OUTCOME MEASURE Renal function and nutritional status. RESULTS At the end of the study, there were no statistically significant differences in renal function between treated and nontreated diabetic patients, whereas treated nondiabetic patients showed a lower decrease in renal function compared with the nontreated group. In both diabetic and nondiabetic patients, the mean body weight and obesity index decreased significantly in treated patients compared with nontreated ones. Serum albumin and prealbumin were stable in all patients during the whole study time, and there were no other signs of malnutrition. CONCLUSION An adequate dietary protein restriction is accepted by patients, and it is well tolerated during a 12-month follow-up. Without any sign of malnutrition, it is possible to get near the ideal body weight and to reduce the obesity index and the body mass index, which are both well-established risk factors for developing cardiovascular pathology. In nondiabetic patients only, we observed a significant slowing of the progression of renal damage.
Collapse
Affiliation(s)
- Carlo Meloni
- Nephrology and Dialysis Unit, S. Eugenio Hospital, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossini B, Cecilia A, Di Franco D, Straccialano E, Casciani CU. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004. [DOI: 10.1053/j.jrn.2004.07.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
17
|
Meloni C, Ghezzi PM, Cipriani S, Petroni S, Del Poeta G, Rossini B, Rossi V, Recino G, Suppo G, Cecilia A, Casciani CU. One Year of Clinical Experience in Postdilution Hemofiltration with Online Reinfusion of Regenerated Ultrafiltrate. Blood Purif 2004; 22:505-9. [PMID: 15539787 DOI: 10.1159/000082040] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/25/2004] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Hemofiltrate reinfusion (HFR) is characterized by the use of regenerated ultrafiltrate as replacement fluid. We set up a new technique, postdilution HFR (PD-HFR), aiming at increasing purification efficiency, treatment tolerance and at reducing inflammatory states. METHODS We performed PD-HFR in 6 uremic patients during 1 year. Dialysis efficacy, dialyzer blood loss and the behavior of cytokines were evaluated. RESULTS No pyrogenic reactions or other adverse events were recorded. Treatment tolerance was excellent. We observed high urea extraction rates and optimal Kt/V values, high beta2-microglobulin (beta2m) extraction rates and a decrease in dialyzer blood loss; also IL-6 and TNF-alpha decreased significantly. CONCLUSIONS Inversion of the standard HFR configuration has allowed us to improve the removal of both urea and beta2m, and to decrease dialyzer blood loss, with an optimal tolerance. Moreover, the decrease in cytokine levels might attenuate the uremic microinflammatory state.
Collapse
Affiliation(s)
- Carlo Meloni
- Nephrology and Dialysis Department, S. Eugenio Hospital, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Spaziani E, Neri T, Guarino E, Tretola V, Pizzuto G, Rossini B, Picconi T, Marsico R, Di Gennaro G, Domini P. [Diet and precancerous gastric lesions: preliminary results of a sampling study of homogeneous population]. MINERVA GASTROENTERO 1995; 41:265-8. [PMID: 8664412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The aim of this study was to analyse the relationship between dietary factors and precancerous gastric lesions in the population of a commune in the province of Latina which, on the basis of data published by RTP-LT, appears to present a striking incidence of so-called diet-dependent tumours. A series of tests was used to evaluate the antioxidising (protective) and pro-oxidising (encouraging) capacity of the following substances in terms of cancerogenesis: lutein, zeoxanthine, cryptoxanthine, lycopene, alpha and beta carotene, total carotenoids, tocopherol, retinol, ascorbic acid, cholesterol, HDL cholesterol, triglycerides and ceruloplasmin. Two sample populations were enrolled in the study: sample A (random) composed of 400 persons (202 males and 198 females) aged between 20 and 80 who underwent esophagogastroduodenoscopy and multiple biopsies of the gastric mucous; sample B (random), representative of the population, composed of 400 persons (200 males and 200 females) aged between 20 and 80, who underwent plasmatic assay of lipid and vitamin status. The results of this study appear to confirm the hypothesis of a correlation between diet and pre-cancerous lesions and suggest that the primary preventive stps take the form of: a) reduced intake of animal fat; b) increased consumption of fresh vegetables.
Collapse
Affiliation(s)
- E Spaziani
- Policlinico Umberto I-Roma VII Patologia Chirurgica, Istituto di II Clinica Chirurgica
| | | | | | | | | | | | | | | | | | | |
Collapse
|